Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; water for injections; sodium chloride; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: sodium chloride; borax; water for injections; aluminium - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

United States - English - NLM (National Library of Medicine)

valneva scotland ltd. - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) 6 ug in 0.5 ml - ixiaro is a vaccine indicated for the prevention of disease caused by japanese encephalitis virus (jev). ixiaro is approved for use in individuals 2 months of age and older. severe allergic reaction (e.g., anaphylaxis) after a previous dose of ixiaro, any other japanese encephalitis virus vaccine, or any component of ixiaro, including protamine sulfate, is a contraindication to administration of ixiaro [see description (11)]. alternatively, because of uncertainty as to which component of the vaccine may be responsible, individuals with a history of severe allergic reaction to another japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with ixiaro is considered. pregnancy category b. reproduction studies have been performed in female rats at doses approximately 300-fold excess relative to the projected human dose (on a mg/kg basis) and have revealed no evidence of impaired fertility or harm to the fetus due to ixiaro. there are, however, no adequate and well‑controlled

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - suspension for injection - encephalitis, tick borne, inactivated, whole virus 2.4 mcg / 0.5 ml - encephalitis, tick borne, inactivated, whole virus - ticovac 0.5 ml is indicated for the active (prophylactic) immunization of adolescents from 16 years of age and adults against tick-borne encephalitis (tbe).

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - suspension for injection - encephalitis, tick borne, inactivated, whole virus 1.2 mcg / 0.25 ml - encephalitis, tick borne, inactivated, whole virus - ticovac junior 0.25 ml is indicated for the active (prophylactic) immunization of children aged from 1 year to 15 years against tick-borne encephalitis (tbe).

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines gmbh - rabies virus (flury lep) inactivated - infus/pdr/oral soln - >= 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - yellow fever virus strain 17d-204 live antigen (unii: py4eet359t) (yellow fever virus strain 17d-204 live antigen - unii:py4eet359t) - yellow fever virus strain 17d-204 live antigen 4.74 [pfu] in 0.5 ml - yf-vax is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories: while the actual risk for contracting yellow fever during travel is probably low, variability of itineraries, behaviors and seasonal incidence of disease make it difficult to predict the actual risk for a given individual living in or traveling to a known endemic or epidemic area. greater risk is associated with living in or traveling to areas of south america and africa where yellow fever infection is officially reported at the time of travel and with traveling outside the urban areas of countries that do not officially report the disease but that lie in a yellow fever endemic zone. some countries require an individual to have a valid international certificate of vaccination or prophylaxis (icvp) if the individual has been in countries either known or thought to harbor yellow fever virus. the certificate becomes valid 10 days after vaccination with yf-vax. (13) (14)

United States - English - NLM (National Library of Medicine)

vetter pharma fertigung gmbh & co. kg - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (unii: dz854i04ze) (japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) - unii:dz854i04ze) - japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) 6 ug in 0.5 ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (korea) - japanese encephalitis virus - solution for injection

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported (korea) - japanese encephalitis virus - solution for injection